Viral Vector Characterization & Analytical Development

In 2023, industry is witnessing a renaissance in viral vector characterization. Spurred by widespread biopharma investment to engineer a new wave of novel capsids and faced with newly launched QbD frameworks by US Pharmacopeia and the FDA’s tightened guidance, increased vector complexity is creating a new era for advanced analytical technologies to ensure precision and accuracy.

In the wake of significant collaborations including Vector Bio and iBET’s for high-throughput characterization, and the likes of Vertex and BMS announcing their priority to build out their internal analytical competencies, the inaugural Viral Vector Characterization & Analytical Development Summit arrives to pave the foundation for teams to further optimize process development and accelerate vector scale-up with GMP compliance in mind.

Uniting Characterization, Analytical, Formulation, Quality, Engineering, CMC and Process leaders, this industry-led summit is your only for cross-learning opportunities across AAV’s, LV’s & RV’s and more – so you can benchmark your work against rapid-analytical method development transforming your peers’ workflows, turnaround, and consistency.

Stay ahead of the curve, and join the likes of Ultragenyx, Kite Pharma, BioMarin, Neogene Therapeutics, Pfizer and many more for a 3-day jam packed agenda, set to tackle your biggest bottlenecks.

Tickets https://go.evvnt.com/1840648-2?pid=10018
Brochure https://go.evvnt.com/1840648-3?pid=10018

Prices:
Drug Developer Pricing - Conference + 2 Workshops USD 4297.00
Drug Developer Pricing - Conference + 1 Workshop USD 3648.00
Drug Developer Pricing - Conference Only USD 2999.00
Solution Provider Pricing - Conference + 2 Workshops USD 5297.00
Solution Provider Pricing - Conference + 1 Workshop USD 4548.00
Solution Provider Pricing - Conference Only USD 3799.00
Academic Pricing - Conference + 2 Workshops USD 3697.00
Academic Pricing - Conference + 1 Workshop USD 3148.00
Academic Pricing - Conference Only USD 2599.00

Speakers: Adeel Lakhani, Associate Scientist - Viral Vector and Analytical Development, Adicet Bio, Alexander Santos, Regulatory Scientist, Voisin Consulting Life Sciences (VCLS), Alice Lin, Director - Analytical Development, Neogene Therapeutics, Li Lin, Graduate Student, University of California at Berkeley, Manuel Mohr, Director and Head of Vector Engineering, Cellinfinity Bio, Mehrshid Alai, Vice President, Kite Pharma, Melba Page, Analytical Laboratory and Quality Control Manager, Moffitt Cancer Center, Nathalie Clement, Vice President - Vector Development Translational & Gene Therapies, Siren Biotechnology, San Francisco, Richard Wu, PhD Candidate, Scott Manalis Laboratory, KOCH Institute for Investigative Cancer Research at MIT, Ronald Toth, Senior Scientist - Characterization, Sanofi, Ting He, Senior Scientist - Adeno-Associated Virus & Pharmaceutical Development, Ultragenyx Pharmaceutical Inc, Vikas Bhat, Director, BioMarin Pharmaceutical, Weidong Xiao, Associate Director of the Gene and Cell Therapy Program, Herman B Wells Venter for Pediatric Research, Indiana University, Ximo Zhang, Senior Manager, Vertex Pharmaceuticals, Yan Gu, Associate Director - Chemistry, Manufacturing, Controls Development & Cell Therapy, Takeda, Yu-Ting Chen, Senior Scientist, Pfizer